What is the Fiscal Year for OS Therapies?
Date: November 13, 2026
OS Therapies's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
New York City, New York, United States
Industry
Healthcare, Biotechnology Research Services
Stock Symbol
OSTX
Website
https://ostherapies.comDescription
OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors. OST-HER2 is completing a PhIIb clinical trial in 4Q2024 with significantly improved Event Free Survival (EFS), and early Overall Survival (OS). OST-tADC is a ph-sensitive novel pre-clinical Drug Conjugate that uses proprietary (IP) Silicon to cover and link the multiple payloads until they are delivered to the acidic cancer environment, dissolving the Silicon - delivering and activating the payloads.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like OS Therapies and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.